GHK-Cu + KPV common uses, half-life, side effects and more

This blend pairs GHK-Cu with KPV for inflammatory skin and soft-tissue recovery. GHK-Cu is a copper tripeptide used for skin and cosmetic repair claims. KPV is the last three residues of the alpha-MSH hormone and dampens inflammatory signaling inside cells. People inject the pair for inflammatory skin conditions, post-procedure recovery, scar remodeling, and soft-tissue repair. Some run it as one premixed vial. Others run two separate vials mixed by hand. The same two peptides also appear inside the larger KLOW blend alongside BPC-157 and TB-500. Topical GHK-Cu is a cosmetic ingredient. The injectable pairing is a gray-market research-only product.

• Cosmetic skin quality such as texture, firmness, and fine lines
• Inflammatory skin conditions such as eczema, dermatitis, and psoriasis
• Post-procedure recovery after laser, microneedling, or minor procedures
• Scar remodeling and soft-tissue repair

Once daily or every other day in 4 to 8 week cycles

Premixed vials hold 50 mg GHK-Cu with either 20 mg or 10 mg KPV. The two peptides are also bought as separate vials and mixed by hand. A premixed vial couples the two doses so the KPV amount is whatever the GHK-Cu draw delivers. A typical injection is 1 to 2 mg of GHK-Cu subcutaneously. Some people inject more. A 50/20 vial at a 2.5:1 ratio delivers 400 to 800 mcg KPV at that draw. A 50/10 vial at a 5:1 ratio delivers 200 to 400 mcg KPV. Both amounts land within the usual range for a KPV dose. Separate vials let people set each dose on their own. Those users often pick around 1 to 2 mg GHK-Cu with a few hundred micrograms of KPV. The vial ratios come from vendor labels rather than from any dose-finding study.

• Premixed 50/20 vials fix a 2.5:1 ratio so every 1 mg of GHK-Cu carries 400 mcg of KPV
• A 50/10 vial fixes a 5:1 ratio so every 1 mg of GHK-Cu carries 200 mcg of KPV
• People who use two separate vials often draw both into one syringe for a single shot
• KLOW adds BPC-157 and TB-500 beyond this pair and should not be logged as this two-peptide blend

No combination pharmacokinetic study exists. The two peptides clear at different rates. KPV has never had a half-life measured in any species. Injected GHK-Cu has no measured human plasma half-life by any route.

GHK-Cu powder and solution are blue to blue-violet from the copper complex. A loss of that blue color can signal degradation. A colorless product is a sign it is not intact GHK-Cu. Protect it from light, heat, and strong chelators such as EDTA.

• Injection-site redness, itching, bruising, soreness, or pain that can begin hours after the shot
• Welts, lumps, or bruising at injection sites that can persist for weeks
• Skin breakouts in the early weeks of injecting
• Headache, nausea, dizziness, fatigue, lightheadedness, or gastrointestinal upset reported by users
• Copper excess can cause abdominal pain, nausea, vomiting, jaundice, unusual bruising, or anemia

• GHK-Cu

  1 to 2 mg per subcutaneous injection

• KPV

  200 to 800 mcg per injection depending on the vial ratio

GHK-Cu is the tripeptide GHK bound to copper. Copper is a required cofactor for two enzymes. Lysyl oxidase cross-links collagen and elastin. Superoxide dismutase defends cells against oxidation. Skin and wound-cell models link GHK-Cu to fibroblast activity, keratinocyte activity, extracellular-matrix turnover, and inflammatory signaling. KPV is the last three residues of alpha-MSH. It enters cells through a peptide transporter called PepT1 that sits on gut lining and immune cells. It then blocks a signaling protein from reaching the nucleus and inflammatory messengers fall. KPV does not compete with alpha-MSH at the pigment receptor so it carries none of the tanning or appetite effects of the parent hormone. The stated rationale for the pair is matrix remodeling from GHK-Cu alongside lower inflammatory signaling from KPV. No study shows the combination outperforms either peptide alone.

Direct evidence for the GHK-Cu plus KPV combination is very low. No human trial, animal study, pharmacokinetic study, or case series of the pair was found. The claim that the two work better together is vendor framing and rests on no test of the combination. GHK-Cu has route-specific evidence that is strongest for topical cosmetic and wound use. Even there the controlled trials have run mixed to negative. Injected GHK-Cu has never been given to a person in a published study. KPV evidence is preclinical. Its gut data is replicated across independent cell and mouse colitis models. The oral and topical KPV claims are weaker because the successful experiments used protective carriers or enhanced skin delivery. The vial ratios come from the market rather than from any dose-finding study.

• The injectable blend is not FDA approved and FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks for immunogenicity and peptide impurities
• KPV has no human exposure data and no animal toxicology study behind it
• Wilson disease, copper overload, significant liver or kidney disease, unexplained anemia, or copper allergy make injected GHK-Cu riskier because a needle bypasses the gut limit on copper
• Pregnancy, breastfeeding, fertility, and pediatric use have no adequate safety data for either peptide
• Research-chemical injectable products may carry wrong identity, wrong mass, copper or peptide impurities, or microbial and endotoxin contamination
• No safety data exists for the two peptides injected together and their combined effects are unstudied